Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of LAD328 in Moderate to Severe Hidradenitis Suppurativa
2025-521865-29-00Phase 2Authorised
- Sponsor
- Almirall
- Start
- Apr 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing LAD328 with Placebo (sodium chloride) (2 arms). Primary endpoints: IHS4-55 response at primary timepoint, Safety – adverse events and 1 more. Planned start Apr 2026; status: authorised.
02
Drugs
LAD328
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-521865-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521865-29-00.